Kura Oncology (KURA) Proxy filing summary

Voting matters and shareholder proposals

• Supplement requests support for the election of Mary T. Szela to the board for a three-year term expiring at the 2029 Annual Meeting.

• No changes to the proxy card or voting instruction form; previously submitted votes remain valid unless changed.

• Shareholders may change or revoke their vote at any time before the final vote at the Annual Meeting.

Board of directors and corporate governance

• Board and Nominating and Corporate Governance Committee annually review each director's outside commitments to assess effectiveness.

• Ms. Szela intends to reduce her public company board memberships before the 2027 Annual Meeting, prioritizing service to this board.

• Board engaged directly with Ms. Szela regarding her time commitments before recommending her for re-election.

• Board will continue to evaluate outside commitments and effectiveness of all directors on an ongoing basis.

Executive summary

• Supplement addresses concerns about Ms. Szela being "overboarded" due to multiple board and executive roles.

• Ms. Szela brings extensive executive and board experience in biotechnology, relevant to the company's strategic priorities.

• Board unanimously recommends voting "For" Ms. Szela's election, citing her qualifications and commitment.